Abstract: A fluidized solidified soil based on gold tailings includes the following raw materials in parts by mass: 75 parts to 80 parts of gold tailings, 5.2 parts to 13 parts of a dispersant solution, and 9 parts to 16 parts of a solidifying material. A preparation method includes the following steps: mixing the gold tailings with the dispersant solution, and then stirring to obtain a suspension slurry of the gold tailings; and adding the solidifying material, and stirring to obtain the fluidized solidified soil. In the present disclosure, the gold tailings are used as a main material, combined with a special dispersant solution and a special solidifying material, and a fluidized solidified soil is prepared with fluidity suitable for pumping and a certain strength after hardening. The fluidized solidified soil prevents the pollution caused by gold tailings landfilling, and can be used as a filling material for various construction projects.

Abstract: Provided are an ROR1-targeting antibody, and a multispecific antibody, a chimeric antigen receptor, an antibody conjugate, a pharmaceutical composition and a kit which comprise same, and the use thereof in the diagnosis/treatment/prevention of diseases associated with ROR1 expression.

Abstract: An engineered immune cell, which expresses (i) a cell surface molecule that specifically recognizes a ligand, (ii) an exogenous interleukin, and (iii) an exogenous Flt3L, XCL2, and/or XCL1; the engineered immune cell can be used for treating cancer, infection, or autoimmune diseases; and compared with a traditional engineered immune cell, the engineered immune cell has significantly improved tumor killing activity.

Abstract: Provided are an NKG2A-targeting antibody, and a multispecific antibody, a chimeric receptor, an antibody conjugate, a pharmaceutical composition and a kit which comprise same, and the use thereof in the diagnosis/treatment/prevention of diseases associated with NKG2A expression.

Abstract: The present invention discloses a method for building a co-culture model for Caco-2/RAW-264.7 cells induced by lipopolysaccharides and an application of the co-culture model. The method includes: 1) culturing Caco-2 cells and RAW-264.7 cells; 2) inoculating the 5 Caco-2 cells onto an AP side of an upper chamber of a Transwell plate, and incubating; 3) inoculating the RAW-264.7 cells onto a 24-well plate, and incubating; 4) transferring the upper chamber of the Transwell plate into the 24-well plate; 5) dissolving lipopolysaccharides in PBS to prepare a stock solution, filtering, and diluting for later use; and 6) adding an LPS-10% DMEM medium on a BL side, incubating, and forming an intestinal inflammation model.

Abstract: Provided in the present invention are a BCMA-targeting single-domain antibody and an encoding nucleotide sequence thereof. Also provided in the present invention are a multispecific antibody, a chimeric antigen receptor, and an antibody conjugate containing the BCMA single domain antibody, and a pharmaceutical composition and kit containing said antibodies, chimeric antigen receptor and antibody conjugate, and the use thereof in the diagnosis/treatment/prevention of diseases associated with BCMA expression.

Abstract: The present invention provides a CD19-targeting humanized antibody, and a multispecific antibody, chimeric receptor, antibody conjugate, pharmaceutical composition, and kit comprising the CD19-targeting humanized antibody, and a use thereof in the diagnosis/treatment/prevention of diseases associated with CD19 expression.

Abstract: Provided is an engineered immune cell. The engineered immune cell expresses (i) a chimeric receptor, and (ii) exogenous CCL3, CCL4 and/or CCL5, has improved tumor killing activity, and can be used to treat cancer, infection or autoimmune diseases.

Abstract: Provided is a chimeric antigen receptor, comprising a ligand-binding domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain. The co-stimulatory domain comprises an intracellular region of an NK-activated receptor or a ligand thereof. Also provided are an engineered immune cell comprising the chimeric antigen receptor and a use thereof in treatment of diseases, such as cancers, autoimmune diseases, and infections.

Abstract: A downhole displacement impact method and an impact drilling tool are provided, which relates to the field of drilling tools. The downhole displacement impact drilling tool includes a flow passing sleeve, a first main shaft, an impact-bearing seat, and a second main shaft that are all formed by annular structures and are connected in sequence from top to bottom. A vibration sleeve, a vibration starting seat, and an impact head are connected in sequence from top to bottom on the impact-bearing seat. The vibration sleeve is connected and fixed to the impact head through a connecting sleeve. The vibration starting seat synchronously rotates with the impact-bearing seat through a spline connection therebetween. The vibration starting seat generates an up-down periodic displacement along an axial direction of the vibration starting seat during rotating.

Abstract: The present invention provides a CD7-targeting humanized antibody, and a multispecific antibody, chimeric antigen receptor, antibody conjugate, pharmaceutical composition, and kit comprising the CD7-targeting humanized antibody, and a use thereof in the diagnosis/treatment/prevention of diseases associated with CD7 expression.

Abstract: Provided is an engineered immune cell. The cell expresses a chimeric antigen receptor comprising an antigen-binding region. The antigen-binding region comprises an anti-CD7 antibody, and the expression of endogenous CD7, at least one TCR/CD3 gene, and at least one MHC-II related gene is suppressed or silenced. Further provided is the use of the engineered immune cell in the treatment of diseases associated with CD7 expression.

Abstract: A pixel structure, a display substrate and a driving method therefor, and a display device. The pixel structure includes a plurality of pixel units; each pixel unit comprises a first sub-pixel, a second sub-pixel, a third sub-pixel, and a central sub-pixel; the central sub-pixel is located in an area enclosed by the first sub-pixel, the second sub-pixel, and the third sub-pixel; the minimum distance from the central sub-pixel to at least one of the first sub-pixel, the second sub-pixel, and the third sub-pixel in a same pixel unit is less than the distance between two adjacent pixel units.

Abstract: A display substrate includes a base substrate including a display region and a peripheral region located on at least one side of the display region. The display region is provided with a plurality of sub-pixels, and at least one of the plurality of sub-pixels includes a light-emitting element and a pixel circuit for driving the light-emitting element. The peripheral region includes a detection region, and the detection region is provided with at least one detection electrode which is electrically connected with a first electrode of the light-emitting element and the pixel circuit through a detection lead wire, to detect electrical performance of the light-emitting element through the detection electrode in a detection stage.

Abstract: The present disclosure belongs to the field of display technologies, and provides a method and apparatus for compensating white point coordinates, and a computer device and a storage medium. The method includes: acquiring target brightness and target white point coordinates of a display module in a black frame insertion mode, wherein the display module includes a backlight; determining white point coordinates corresponding to the target brightness to be reached by the backlight in the black frame insertion mode and in an always-on mode, respectively; and compensating the target white point coordinates based on a difference value between the white point coordinates in the always-on mode and the white point coordinates in the black frame insertion mode.

Abstract: Provided is a matching method for manufacturing a liquid crystal display (LCD) device. The method includes: acquiring luminance data of a plurality of backlight modules and transmittance data of a plurality of LCD panels under a same driving condition; acquiring N backlight groups by grouping the plurality of backlight modules based on the luminance data; acquiring N panel groups by grouping the plurality of LCD panels based on the transmittance data; and determining a corresponding relationship between the backlight group and the panel group.

Abstract: A detection circuit, a driving circuit, and a display panel and a driving method therefor are provided. The detection circuit includes an acquisition circuit and a processing circuit. The acquisition circuit includes a test transistor and an energy storage element, where, for the test transistor, a control end is configured to be coupled to the data signal terminal, a first end is configured to be written with a detection signal, and a second end is coupled to the energy storage element; and a structural characteristic of the test transistor is identical to a structural characteristic of the driving transistor. The processing circuit is coupled to the second end of the test transistor, and configured to detect a voltage at the second end of the test transistor as a detection voltage and regulate the data signal according to the detection voltage.

Abstract: A chimeric antigen receptor, containing a ligand binding domain, a transmembrane domain, a co-stimulatory domain, and an intracellular signaling domain, the co-stimulatory domain containing CD94 and/or LT? intracellular regions. The present invention further relates to engineered immune cells containing such a chimeric antigen receptor, and uses thereof in the treatment of diseases, such as cancer, autoimmune diseases, and infections.

Abstract: Provided is an engineered immune cell. The expressions of at least one MHC related gene and at least one NK activating receptor binding molecule are suppressed or silenced, so as to suppress the killing of the engineered immune cell by NK cells. Also provided are a pharmaceutical composition comprising the engineered immune cell and use of the engineered immune cell in preparation of drugs for treatment of cancer, infection, or autoimmune diseases.

Abstract: The invention relates to an engineered immune cell comprising: (a) a first nucleic acid sequence encoding a chimeric antigen receptor or a chimeric antigen receptor encoded thereby, said chimeric antigen receptor comprises a first antigen binding region, a transmembrane domain, and an intracellular signaling domain; and (b) a second nucleic acid sequence encoding an Fc fusion polypeptide or an Fc fusion polypeptide encoded thereby, said Fc fusion polypeptide comprises a second antigen binding region and an Fc region, wherein the first antigen binding region and the second antigen binding region are not scFv at the same time. The invention also relates to compositions comprising the engineered immune cells of the invention, and the use of the engineered immune cells/compositions in the treatment of cancer.